Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success ...

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.

Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course ...

The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company." ...

Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to ...

A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk ...

Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three ...

Skyhawk Therapeutics, a Boston-based biotechnology company, has unveiled final results from a small study testing a once-daily, “RNA splicing” pill as a treatment for Huntington’s disease.

Armed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.

First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers ...

As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings ...